Elena Moreno-Olmedo

198 posts

Elena Moreno-Olmedo banner
Elena Moreno-Olmedo

Elena Moreno-Olmedo

@elenmol2

RadOnc-MRL-consultant at @harleystclinic @HCAhospitalsUK. AdaptiveRT. MRIguided.HDR-BT. SABR. Prostate, Gyn, H&N, Oligomets.

London, England Katılım Nisan 2018
424 Takip Edilen255 Takipçiler
Sabitlenmiş Tweet
Elena Moreno-Olmedo
Elena Moreno-Olmedo@elenmol2·
🧵Glad to share our 10y results at #ASTRO23. 🔎looking for the biological benefit of ultrahypofractionation, safety and confort of the patient and cost-effectiveness of the process, this prospective study was initiated in 2010.
Elena Moreno-Olmedo tweet media
English
1
6
27
5.4K
Elena Moreno-Olmedo retweetledi
Gerry Hanna
Gerry Hanna@gerryhanna·
Super paper by @elenmol2 et al from @ucl + @TheChristieNHS on #MRLinac guided central lung #SABR 📢Check out the amazing cine movies of adaption to target on the journal website (screenshot below) ➡️No grade ≥ 3 toxicities ➡️Median FU of 28 months, 66.7% of patients alive ➡️Median PFS = 5.8 months, OS = 20 months 🔗 advancesradonc.org/article/S2452-…
Gerry Hanna tweet media
English
4
2
11
1.6K
Elena Moreno-Olmedo retweetledi
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
STOPCAP at #ESMO26 Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS. Restricted to <5 bone or low volume mets on conventional imaging. No interaction with other patient/tumor characteristics.
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
English
3
52
111
4.8K
Elena Moreno-Olmedo retweetledi
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
As expected people resist letting go of dogma. Lets review the common examples people grasp at: 1. Nodal field size: cited as why GETUG01 was negative (S1/S2), then cited why RTOG 9413 was negative (L5/S1), then POP-RT positive (L4/L5), but definitive trial of RTOG 0924 (L4/L5) negative
Daniel E Spratt@DrSpratticus

#astro25 @NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT. Negative trial -OS no difference -PCSM no difference -DM no difference -BCR was not SS different with only 4% difference at 10 years. -toxicity increased 3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924. Goodbye WPRT

English
5
17
53
9.5K
Elena Moreno-Olmedo retweetledi
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
#astro25 @NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT. Negative trial -OS no difference -PCSM no difference -DM no difference -BCR was not SS different with only 4% difference at 10 years. -toxicity increased 3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924. Goodbye WPRT
English
16
68
185
49.9K
Elena Moreno-Olmedo retweetledi
Dr. Andrew Loblaw
Dr. Andrew Loblaw@DrAndrewLoblaw·
Critically important. We have 2 RCTs addressing this question: @GiulioFrancoli1 #ARTO (MDT + abi > abi) and T Niazi #PCS IX (MDT + Enza > Enza) Also have #EXTEND and #RADIOSA showing MDT + ADT > ADT or MDT in mHSCP. In my mind leading question is doublet ARPI + MDT in mHSPC
Pierre Blanchard, MD@PBlanchardMD

Another proof that metastasis directed therapy improves outcomes, this time in castration resistant #prostatecancer Congrats to the PCS IX team! author link at @TheLancetOncol: authors.elsevier.com/a/1liJQ5EIIgTS…

English
6
21
55
4.5K
Elena Moreno-Olmedo retweetledi
Advanced Prostate Cancer Consensus Conference
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial sciencedirect.com/science/articl… The phase 2 EXTEND trial showed that in patients with oligometastatic #ProstateCancer adding metastasis-directed therapy (MDT) to androgen deprivation therapy (ADT)💊 significantly improved progression-free survival compared with ADT alone (36 vs 17 months in combined analysis), with consistent benefits in radiologic and castration resistance–free survival; translational analyses revealed that MDT + ADT enhanced systemic immune activation, particularly T-cell receptor dynamics, suggesting both a durable clinical benefit and potential synergy with future immunotherapy strategies. @AlexSherryMD @BSiddiquiMD @cara_haymaker @ASeoMDPhD @kieko_hara @StephenChunMD @ChapinMD @matthewdeek @woodlandscancer @aaparicioMD @DrLCohen @AReubenPhD @sumit_subudhi @ChadTangMD @silkegillessen @AOmlin @nataliagandur @bavilima @yekeduz_emre
Advanced Prostate Cancer Consensus Conference tweet media
English
0
32
61
5.8K
Elena Moreno-Olmedo
Elena Moreno-Olmedo@elenmol2·
MR- vs CT-guided: nearly half GU toxicity!!💥💥💥
European Urology@EUplatinum

📢 New in European Urology @AmarUKishan et al: 🎯 MRI-guided SBRT for prostate cancer significantly reduces late GU and GI toxicity vs CT-guided SBRT at 2 years! 🔬 In the MIRAGE RCT, MRI guidance with tighter margins (2 mm) halved GU toxicity (27% vs 51%) and markedly reduced GI toxicity (1.4% vs 9.5%). 💡 Also linked to better bowel & sexual function scores. Proof-of-principle for aggressive margin reduction using advanced imaging. 📄 Read more: buff.ly/bIJ3ocU #ProstateCancer #Radiotherapy #MRI #SBRT #UroRadOnc #EurUrol

English
0
0
0
84
Elena Moreno-Olmedo retweetledi
European Urology
European Urology@EUplatinum·
📢 New in European Urology @AmarUKishan et al: 🎯 MRI-guided SBRT for prostate cancer significantly reduces late GU and GI toxicity vs CT-guided SBRT at 2 years! 🔬 In the MIRAGE RCT, MRI guidance with tighter margins (2 mm) halved GU toxicity (27% vs 51%) and markedly reduced GI toxicity (1.4% vs 9.5%). 💡 Also linked to better bowel & sexual function scores. Proof-of-principle for aggressive margin reduction using advanced imaging. 📄 Read more: buff.ly/bIJ3ocU #ProstateCancer #Radiotherapy #MRI #SBRT #UroRadOnc #EurUrol
European Urology tweet media
English
1
15
55
5.4K
Elena Moreno-Olmedo retweetledi
GenesisCareUK
GenesisCareUK@GenesisCare·
Proud to see EMERALD Trial findings presented at #ESTRO2025 by Dr. Somnath Mukherjee! Watch this short video from @drjamesgood to discover how MR-guided SABR is transforming pancreatic cancer treatment 🎥 Click to download ESTRO presentation 👉🏽 bit.ly/4d4MHbC
English
2
3
6
414
Elena Moreno-Olmedo
Elena Moreno-Olmedo@elenmol2·
☢️For those interested in more technical details, don’t miss our dosimetric poster (E25-3471)!!
English
0
0
0
37
Elena Moreno-Olmedo retweetledi
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
🚨10y results of HYPO RT PC at #ESTRO25 Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT 1. Non inferior for FFS (even better?) 2. Similar bPFS, DMFS, ADT use, OS 3. Similar GU/GI tox (except transient flare at 1y for UHF)
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
English
4
57
151
12.4K

Keşfet

@ucl @TheChristieNHS @NRGonc @GiulioFrancoli1 @AlexSherryMD @BSiddiquiMD @cara_haymaker @ASeoMDPhD